Analyzing Halozyme Therapeutics (NASDAQ:HALO) & AquaBounty Technologies (NASDAQ:AQB)

Halozyme Therapeutics (NASDAQ:HALO) and AquaBounty Technologies (NASDAQ:AQB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings for Halozyme Therapeutics and AquaBounty Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1	4	7	1	2.62
AquaBounty Technologies	1	0	0	0	1.00

Halozyme Therapeutics currently has a consensus target price of $108.18, suggesting a potential upside of 6.39%. Given Halozyme Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Halozyme Therapeutics is more favorable than AquaBounty Technologies.

Earnings and Valuation

This table compares Halozyme Therapeutics and AquaBounty Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40 billion	8.30	$316.89 million	$3.93	25.87
AquaBounty Technologies	$2.47 million	1.95	-$18.49 million	($0.69)	-1.34

Halozyme Therapeutics has higher revenue and earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Halozyme Therapeutics and AquaBounty Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	26.93%	751.81%	23.84%
AquaBounty Technologies	N/A	-147.07%	-43.18%

Risk & Volatility

Halozyme Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Insider & Institutional Ownership

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 1.0% of AquaBounty Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Halozyme Therapeutics beats AquaBounty Technologies on 13 of the 14 factors compared between the two stocks.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

About AquaBounty Technologies

AquaBounty Technologies, Inc. is a biotechnology and aquaculture company focused on developing and producing land-raised Atlantic salmon. Its principal product is AquAdvantage salmon, a genetically engineered salmon designed to reach market size more quickly than conventional Atlantic salmon. The company has pursued land-based, contained aquaculture systems intended to reduce reliance on ocean-based farming and improve production efficiency. AquAdvantage salmon incorporates a growth-hormone gene from Chinook salmon and a regulatory sequence from ocean pout.